Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. - Wikidata - wikimedia - TriplyDB

Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations.

Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations.

http://www.wikidata.org/entity/Q34746064

about

A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study PCR-induced transitions are the major source of error in cleaned ultra-deep pyrosequencing data TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing Model for assessment of proficiency of human immunodeficiency virus type 1 sequencing-based genotypic antiretroviral assays Japanese external quality assessment program to standardize HIV-1 drug-resistance testing (JEQS2010 program) using in vitro transcribed RNA as reference material.Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010.Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China.

P2860

Q28469027-6135DA59-C2DC-4FA7-8DBF-E952B38CDC15 Q30657886-DA8CB3CF-95B8-491A-8EF2-380EF999BBBE Q33824827-92941B21-1DD9-4017-A18D-4FE71A326D57 Q33899918-3B51B105-E178-475A-ACA5-029A6F670ECB Q34041819-988F6833-AEF3-4A91-93FB-3E993DB5AF0D Q35141797-D26B5554-CE92-4050-A171-1BDB590B6FB4 Q35917555-8E807D17-2FA8-48F1-B357-B6492250E1ED Q36315090-5DF723FF-96C2-4582-BEE3-FF821440D998 Q37005868-BD670816-1DA4-4C90-AF11-577266EB4BAD Q37189622-7E2C065A-245A-43B9-B635-F413AACC46EB Q54695288-BD376149-315C-42A2-8DF2-2939FED54E0A

P2860

Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations.

http://www.wikidata.org/entity/Q34746064

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Quality assessment program for ...... of drug resistance mutations.

@ast

Quality assessment program for ...... of drug resistance mutations.

@en

Quality assessment program for ...... of drug resistance mutations.

@nl

type

label

Quality assessment program for ...... of drug resistance mutations.

@ast

Quality assessment program for ...... of drug resistance mutations.

@en

Quality assessment program for ...... of drug resistance mutations.

@nl

prefLabel

Quality assessment program for ...... of drug resistance mutations.

@ast

Quality assessment program for ...... of drug resistance mutations.

@en

Quality assessment program for ...... of drug resistance mutations.

@nl

P1433

Q34746064-83BD434D-CF9F-47B5-ACC1-0A95BC006BFD

P1476

Q34746064-7FCA35DF-3A0B-4DA8-B731-50828C6D57BB

P2093

Q34746064-416973A7-A250-4F28-8160-E7A07EF9952A

Q34746064-494FDCDB-C9AC-457F-A875-E5A11F5DDF17

Q34746064-54D9F398-8805-498C-82AA-83BC26161AEE

Q34746064-6F65BF36-302A-4689-AEF0-65F84E2B7134

Q34746064-82DA9B0B-225D-4715-97EE-9EA3D6A5F551

Q34746064-99E4735B-4A00-48E0-B3C3-68A047A4B0CB

Q34746064-A11A0D45-2637-4CBE-A123-EA3608E95FBF

Q34746064-B8AE1E02-9BE6-4F6D-B6BD-88AC8918B343

P2860

Q34746064-0B70D624-D016-4D69-A7B5-3493DC36A89B

Q34746064-15A9B841-8257-4DC1-9EF2-CC84575A67D1

Q34746064-18A30180-6581-4A9D-BAC4-9E68197F24FB

Q34746064-1E191C19-1BA1-455D-95D3-04B4931C3F59

Q34746064-437C2DD8-F065-4FF8-A56B-F4169AC41540

Q34746064-4A6BD0C0-3FAB-40C8-A1F1-FDD56483DCE6

Q34746064-6F8E456C-9623-4291-A1E0-42EAD88C9BA5

Q34746064-760EF43B-FC43-4242-A825-6CBB2EE5069B

Q34746064-9F912FBD-EF73-43A1-B398-AB62F12CC475

Q34746064-AF614491-388E-4B0E-8E59-9E237EF476CA

P304

Q34746064-B1C8623C-0CB0-4B19-B716-34E013CF0181

P31

Q34746064-DC81BC8D-808C-40F5-9195-2FA3D6612E74

P356

Q34746064-CEE561BC-6924-4E8D-A47E-5F74CC2508DD

P407

Q34746064-455FB443-F7A7-4021-A827-490FA5230A16

P433

Q34746064-6FC57163-78FE-4940-A801-46B0CDF611D8

P478

Q34746064-D1A015C9-5E68-4975-AB04-37BC0C6D6424

P577

Q34746064-AD204F8B-EF5F-4EEC-AFB8-2CE83310C8C0

P5875

Q34746064-F6F7C1E8-3832-4D72-BA9D-00B363829036

P698

Q34746064-92C18E88-F2AB-4790-8620-DEDC8803EDF6

P921

Q34746064-F4F3F6A3-FFF2-4671-8808-51F361B5CF56

P932

Q34746064-A7C63EDE-1237-4DA9-AB00-510B7D037161

P356

JCM.41.1.227-236.2003

P1433

Journal of Clinical Microbiology

P1476

Quality assessment program for ...... of drug resistance mutations.

@en

P2093

Christiansen FT

http://www.w3.org/2001/XMLSchema#string

Dax EM

http://www.w3.org/2001/XMLSchema#string

Emery S

http://www.w3.org/2001/XMLSchema#string

French M

http://www.w3.org/2001/XMLSchema#string

Gizzarelli L

http://www.w3.org/2001/XMLSchema#string

Hales G

http://www.w3.org/2001/XMLSchema#string

Land S

http://www.w3.org/2001/XMLSchema#string

Sayer DC

http://www.w3.org/2001/XMLSchema#string

P2860

A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy

Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods.

A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy- and dideoxyribonucleotides.

High-resolution HLA-DPB typing based upon computerized analysis of data obtained by fluorescent sequencing of the amplified polymorphic exon 2.

High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients

Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates.

Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.

P304

227-236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JCM.41.1.227-236.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10959253

http://www.w3.org/2001/XMLSchema#string

P698

12517853

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

149552

http://www.w3.org/2001/XMLSchema#string